Cardiovascular Calcification Market

Market Overview:

The 7 major cardiovascular calcification markets reached a value of US$ 119.4 Billion in 2023. Looking forward, IMARC Group expects the 7MM to reach US$ 190.6 Billion by 2034, exhibiting a growth rate (CAGR) of 4.34% during 2024-2034.

The cardiovascular calcification market has been comprehensively analyzed in IMARC's new report titled "Cardiovascular Calcification Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Cardiovascular calcification refers to the abnormal deposition of calcium in the walls of arteries and heart valves, leading to their stiffening and impaired function. This process is often associated with atherosclerosis, a common condition characterized by plaque buildup in the arteries. As calcium accumulates in the arterial walls, it can result in reduced elasticity, blood flow obstruction, and increased cardiovascular risk. The symptoms of this disorder may not manifest until the condition has progressed significantly. Patients might experience chest pain, shortness of breath, and fatigue due to compromised blood supply to vital organs and tissues. The diagnosis of the ailment typically involves several medical imaging techniques, like X-rays, CT scans, ultrasounds, etc. These methods can visualize the presence and extent of calcification in the arteries and heart valves. Additionally, the measurement of biomarkers related to calcium metabolism and cardiovascular health, like serum calcium and phosphate levels, can aid in assessing the risk and progression of cardiovascular calcification.

The increasing incidence of calcium deposits in arterial walls and valves, which lead to the stiffening and narrowing of vital pathways in the circulatory system, is primarily driving the cardiovascular calcification market. In addition to this, the inflating utilization of innovative treatments, such as statins, bisphosphonates, vitamin K2, etc., to manage the progression and mitigate the effects of the ailment is also creating a positive outlook for the market. Moreover, the widespread adoption of lifestyle interventions that promote heart health, including tailored dietary plans and regular aerobic exercises, is further bolstering the market growth. Apart from this, the rising usage of novel technologies, like endovascular atherectomy, which ensures the meticulous removal of calcified plaques from arterial walls, thereby boosting the quality of life for patients, is acting as another significant growth-inducing factor. Additionally, the escalating application of physical and rehabilitative therapies, since they are pivotal in enhancing cardiovascular endurance, fostering flexibility, and improving overall cardiac health, is also propelling the market growth. Furthermore, the emerging inclination towards research in the molecular and genetic underpinnings of cardiovascular calcification, aiming to unearth the genomic anomalies causing the disorder, is expected to drive the cardiovascular calcification market during the forecast period.

IMARC Group's new report provides an exhaustive analysis of the cardiovascular calcification market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for cardiovascular calcification and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the cardiovascular calcification market in any manner.

Time Period of the Study

• Base Year: 2023
• Historical Period: 2018-2023
• Market Forecast: 2024-2034

Countries Covered

• United States
• Germany
• France
• United Kingdom
• Italy
• Spain
• Japan
   

Analysis Covered Across Each Country

• Historical, current, and future epidemiology scenario
• Historical, current, and future performance of the cardiovascular calcification market
• Historical, current, and future performance of various therapeutic categories in the market
• Sales of various drugs across the cardiovascular calcification market
• Reimbursement scenario in the market
• In-market and pipeline drugs

Competitive Landscape:

This report also provides a detailed analysis of the current cardiovascular calcification marketed drugs and late-stage pipeline drugs.

In-Market Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

Late-Stage Pipeline Drugs

• Drug Overview
• Mechanism of Action
• Regulatory Status
• Clinical Trial Results
• Drug Uptake and Market Performance
   

*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.

Key Questions Answered in this Report:

Market Insights

• How has the cardiovascular calcification market performed so far and how will it perform in the coming years?
• What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
• What was the country-wise size of the cardiovascular calcification market across the seven major markets in 2023 and what will it look like in 2034?
• What is the growth rate of the cardiovascular calcification market across the seven major markets and what will be the expected growth over the next ten years?
• What are the key unmet needs in the market?
   

Epidemiology Insights

• What is the number of prevalent cases (2018-2034) of cardiovascular calcification across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cardiovascular calcification by age across the seven major markets?
• What is the number of prevalent cases (2018-2034) of cardiovascular calcification by gender across the seven major markets?
• How many patients are diagnosed (2018-2034) with cardiovascular calcification across the seven major markets?
• What is the size of the cardiovascular calcification patient pool (2018-2023) across the seven major markets?
• What would be the forecasted patient pool (2024-2034) across the seven major markets?
• What are the key factors driving the epidemiological trend of cardiovascular calcification?
• What will be the growth rate of patients across the seven major markets?
   

Cardiovascular Calcification: Current Treatment Scenario, Marketed Drugs and Emerging Therapies

• What are the current marketed drugs and what are their market performance?
• What are the key pipeline drugs and how are they expected to perform in the coming years?
• How safe are the current marketed drugs and what are their efficacies?
• How safe are the late-stage pipeline drugs and what are their efficacies?
• What are the current treatment guidelines for cardiovascular calcification drugs across the seven major markets?
• Who are the key companies in the market and what are their market shares?
• What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the cardiovascular calcification market?
• What are the key regulatory events related to the cardiovascular calcification market?
• What is the structure of clinical trial landscape by status related to the cardiovascular calcification market?
• What is the structure of clinical trial landscape by phase related to the cardiovascular calcification market?
• What is the structure of clinical trial landscape by route of administration related to the cardiovascular calcification market?